R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience
Crossref DOI link: https://doi.org/10.1007/s00277-017-3180-x
Published Online: 2017-11-16
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Widmer, Fabienne
Balabanov, Stefan
Soldini, Davide
Samaras, Panagiotis
Gerber, Bernhard
Manz, Markus G.
Goede, Jeroen S.
License valid from 2017-11-16